PolyPid Connects with Investors at Upcoming Conferences
PolyPid Ltd. (NASDAQ: PYPD), an innovative biopharmaceutical company, is gearing up to make a significant impact at three major investor conferences this fall. The company's dedication to improving surgical outcomes is clear as its management team prepares to share valuable insights and updates with both potential and existing investors.
Scheduled Conferences
H.C. Wainwright 26th Annual Global Investment Conference
Beginning on September 9, 2024, PolyPid will take part in the H.C. Wainwright conference. Attendees can access PolyPid's presentation on-demand through the conference platform starting at 7:00 AM ET.
Lytham Partners Fall 2024 Investor Conference
The Lytham Partners Fall conference will feature a unique fireside chat with PolyPid, available on-demand from October 1, 2024. This presentation will be accessible for 90 days on the Lytham investor portal.
Sidoti & Company Micro-Cap Virtual Conference
Additionally, PolyPid will participate in the Sidoti & Company Micro-Cap Virtual Conference, scheduled for November 13-14, 2024. This event presents another excellent opportunity for investors to engage with the management team.
Engaging with Investors
PolyPid's management team is eager to connect with investors during these conferences. They will offer one-on-one meetings, providing a personalized experience tailored to address investor questions and interests. Investors interested in scheduling discussions with PolyPid are encouraged to reach out directly to the conference organizers.
About PolyPid Ltd.
PolyPid is a late-stage biopharmaceutical company dedicated to transforming surgical outcomes. Their proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables localized and controlled release of therapeutics. This cutting-edge approach uses Active Pharmaceutical Ingredients (APIs) for precise drug delivery over extended durations, ranging from days to months. PolyPid's flagship product, D-PLEX100, is currently in Phase 3 trials aimed at preventing surgical site infections in abdominal colorectal procedures. Looking ahead, the company is also in the process of developing OncoPLEX, which is undergoing preclinical testing to assess its potential for treating solid tumors, including glioblastoma.
For further details about PolyPid and its initiatives, interested individuals can visit the company's official website. The management also encourages following their social media channels for real-time updates on the company’s projects and upcoming events.
Frequently Asked Questions
What is PolyPid's main focus?
PolyPid is dedicated to enhancing surgical outcomes through innovative biopharmaceutical products.
When will PolyPid participate in the H.C. Wainwright conference?
PolyPid will present at the H.C. Wainwright 26th Annual Global Investment Conference starting September 9, 2024.
What product is PolyPid currently testing in clinical trials?
PolyPid's lead product candidate, D-PLEX100, is in Phase 3 clinical trials aimed at preventing surgical site infections.
How can investors engage with PolyPid during the conferences?
Investors can arrange one-on-one meetings with PolyPid management during the various conferences.
What future developments is PolyPid exploring?
PolyPid is investigating the treatment of solid tumors with their product OncoPLEX, which is currently in preclinical stages.
